4.6 Article

Vitamin D status was not associated with 'one-year' progression of coronary artery disease, assessed by coronary angiography in statin-treated patients

期刊

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
卷 22, 期 5, 页码 594-602

出版社

OXFORD UNIV PRESS
DOI: 10.1177/2047487314522137

关键词

Vitamin D; 25-hydroxyvitamin D; calcifediol; coronary artery disease; atherosclerosis; disease progression; coronary angiography

资金

  1. Norwegian Ministry of Health and Care Services
  2. Western Norway Regional Health Authority
  3. Department of Heart Disease at Haukeland University Hospital, Bergen
  4. Meltzer Foundation, Bergen, Norway

向作者/读者索取更多资源

Background Low vitamin D status is associated with increased risk of cardiovascular disease and may be involved in atherosclerosis. Our aim was to assess the association between vitamin D status and the progression of coronary artery disease (CAD). Methods and Results We measured 25-hydroxyvitamin D3 (25OHD3) by liquid chromatography tandem mass spectrometry (LC-MS/MS) in plasma from 348 participants with established CAD (84% males, meanstandard deviation (SD) age 6010 years) of the Western Norway B-vitamin Intervention Trial (WENBIT, 1999-2006). The patients underwent invasive coronary angiography (CA) and percutaneous coronary intervention at baseline and a second CA after 302 +/- 79 days of follow-up. From the angiograms, minimal lumen diameter (MLD) and diameter stenosis (DS) of atherosclerotic lesions were obtained. Significant CAD in non-intervened vessels was found in 309 coronary arteries from 183 participants either at baseline and/or at follow-up. To assess the association between levels of 25OHD3 and CAD progression in non-intervened vessels, we applied a linear quantile fitted mixed effects model with MLD or DS measured at follow-up as a function of continuous 25OHD3 concentrations. There were no statistically significant associations between plasma 25OHD3 concentrations (median: 63.9, 95% confidence interval (CI): 48.1-78.5nmol/l) measured at baseline and the follow-up measures of either MLD (estimated effect per 10nmol/l increase of 25OHD3 and 95% CI: -0.015 (-0.032-0.002) mm, p=0.088) or DS (0.225 (-0.354-0.804) percentage points, p=0.444). Multivariate adjustment did not alter these results. Conclusion Plasma 25OHD3 levels were not associated with one-year' progression of CAD, assessed by CA in statin-treated patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据